MPP-Home

en / fr

New WHO hepatitis C treatment guidelines

The MPP welcomes the new global guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection published by the World Health Organization.

To fight hepatitis C, let’s improve early diagnostics and access to medicines, and push for global support

Blog post by Giten Khwairakpam, Community and Policy Program Manager, amfAR/TREAT Asia programme, Bangkok and member of the MPP’s Expert Advisory Group for Hepatitis.

The Medicines Patent Pool Presents New Five-Year Strategy For Improving Access To Priority Treatments In Developing Countries

Strategy and Related Feasibility Study Call for the Expansion of the MPP’s Mandate to Patented Medicines on the World Health Organization’s Model List of Essential Medicines

Exploring The Expansion Of The Medicines Patent Pool’s Mandate To Patented Essential Medicines

A Feasibility Study Of The Public Health Needs And Potential Impact

Who We Are

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to HIV, hepatitis C and tuberculosis treatments in low- and middle-income countries.

Vision & Mission

Our Model

Strategy

Governance & Team

Funding

Who We Work With

MedsPaL

The Medicines Patents & Licences Database

The MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.

Additional information and disclaimers

Transparency

All MPP licences are publicly available in their entirety on our website. This is unprecedented in the pharmaceutical field.

Licence Overview

Update on Progress of Sublicensees

Forecasting

Forecasting Tool

MPP in Numbers

Hover over the numbers to find out more

9 patent holders with MPP signed agreements

17 million patient-years through MPP’s generic partners from January 2012 to December 2017

25 generic manufacturers and product developers sublicensed from the MPP

17 products licensed to the MPP

130+

130+ ongoing pharmaceutical development projects

87% to 91%

87% to 91% of people living with HIV in developing countries covered by the MPP adult licences

92 to 131

92 to 131 countries covered by MPP adults licences

553

553 million dollars saved, from January 2012 to December 2017

Latest News

28 July 2018

The MPP welcomes the new WHO hepatitis C treatment guidelines

Geneva, 28 July 2018 - The Medicines Patent Pool (MPP) welcomes the new global guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection published today by the World Health Organization. These guidelines recommend treating all people aged 12 and above living with chronic hepatitis C virus (HCV) infection (with the exception of pregnant women) and recommends the use of pan-genotypic regimens. The MPP signed a licence agreement for pan-genotypic direct-acting antiviral daclatasvir (DAC) and its combinations with Bristol-Myers Squibb in November 2015. Since then, ten generic manufacturing partners of the MPP signed a licence to produce lower-cost versions of these products for sale in 112 low- and middle-income countries. Four MPP licensees have already filed daclatasvir (DAC) 30mg and 60mg for regulatory approval through the WHO Prequalification Program and three more plan to do so in 2019. One manufacturer has already received approval from the Expert Review Pan...

24 May 2018

The Medicines Patent Pool Presents New Five-Year Strategy for Improving Access to Priority Treatments in Developing Countries

Strategy and Related Feasibility Study Call for the Expansion of the MPP’s Mandate to Patented Medicines on the World Health Organization’s Model List of Essential Medicines Geneva, 24 May 2018 — The Medicines Patent Pool Foundation (MPP) released its five-year strategic plan during a side event at the 71st World Health Assembly this evening. The strategy calls for renewed efforts to reach people living with HIV, hepatitis C and tuberculosis in low- and middle-income countries (LMICs) with better-adapted, affordable medicines. Based on a feasibility study also presented at the MPP-partner event, The Path to Universal Health Coverage: Access to Affordable Treatments, the plan supports the expansion of the MPP model to other patented medicines with high medical value, starting with small molecules on the World Health Organization Model List of Essential Medicines (EML). “Over the past eight years, the MPP has made significant inroads in supporting the scale-up of new antiretrovirals, as well as curative...

22 May 2018

MPP Statement on the Global strategy and plan of action on public health, innovation and intellectual property (GSPOA) at the 71st World Health Assembly

Meeting: Seventy-first World Health Assembly (A71/1) Agenda Item: 11.6 Global strategy and plan of action on public health, innovation and intellectual property Statement: The Medicines Patent Pool welcomes the report by the Director-General on the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPOA). Over the past 10 years, the Global Strategy has provided a very important roadmap on strategies to promote innovation, access and technology transfer. The MPP itself is a good example of Strategy implementation. At the time of the Strategy’s adoption, a patent pool in public health to facilitate innovation and access was an interesting idea that may have seemed ambitious to many. Today, MPP, an organization funded by Unitaid, has grown to become a critical component of the international response to HIV, hepatitis and tuberculosis. The document recommends expansion of the MPP to other diseases or technologies. A focus on essential medicines represents an i...

Videos

Unable to load video, please allow cookie

Endorsements

“WHO welcomes the announcement that the Medicines Patent Pool is expanding its mandate to include patented medicines on WHO’s Model List of Essential Medicines in its patent pooling and voluntary licensing initiatives. It is a welcome and significant step f...”

Unable to load twitter timeline, please allow cookie